CoChat

Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects

Moradei, O., Maroun, C., Paquin, I., Vaisburg, A. · 2005 · Current Medicinal Chemistry-Anti-Cancer Agents
Cited by 84

The DOI matches its Crossref record.

Abstract

Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are enzymes that catalyze the deacetylation and acetylation of lysine residues located in the NH(2) terminal tails of histones and non-histone proteins. Perturbation of this balance is often observed in human cancers and inhibition of HDACs has emerged as a novel therapeutic strategy against cancer. To date, more that 30 groups, academic and industrial, are involved in research related to these target enzymes. Over the past year, dozens of research papers and patent applications describing new HDAC inhibitors belonging to different structural classes have been disclosed. The present review highlights the latest developments in design and synthesis of HDAC inhibitors -- potential anti-cancer drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1568011054866946

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 84

Metadata

Authors
Moradei, O., Maroun, C., Paquin, I., & Vaisburg, A.
Venue
Current Medicinal Chemistry-Anti-Cancer Agents
Published
2005-09-01
Volume
5
Issue
5
Pages
529-560
ISSN
1568-0118 (ISSN-L)
OpenAlex
W2022093757
Cited by
84
References
0
FWCI
4.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects. https://app.cochat.ai/papers/10.2174/1568011054866946
The paper
Moradei, O., Maroun, C., Paquin, I., & Vaisburg, A. (2005). Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects. Current Medicinal Chemistry-Anti-Cancer Agents. https://doi.org/10.2174/1568011054866946

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.